Suppliers and packagers for generic pharmaceutical drug: NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

NAPROXEN SODIUM; PSEUDOEPHEDRINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Aurobindo Pharma	NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE	naproxen sodium; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211360	ANDA	Aurohealth LLC	58602-816-67	2 BLISTER PACK in 1 CARTON (58602-816-67) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2022-06-01
Aurobindo Pharma	NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE	naproxen sodium; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211360	ANDA	Aurohealth LLC	58602-816-72	3 BLISTER PACK in 1 CARTON (58602-816-72) / 8 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2022-06-01
Aurobindo Pharma	NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE	naproxen sodium; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211360	ANDA	Aurohealth LLC	58602-816-83	1 BLISTER PACK in 1 CARTON (58602-816-83) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2022-06-01
Aurobindo Pharma	NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE	naproxen sodium; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211360	ANDA	Aurohealth LLC	58602-832-67	2 BLISTER PACK in 1 CARTON (58602-832-67) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2022-06-01
Aurobindo Pharma	NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE	naproxen sodium; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211360	ANDA	Aurohealth LLC	58602-832-83	1 BLISTER PACK in 1 CARTON (58602-832-83) / 10 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2022-06-01
Aurobindo Pharma	NAPROXEN SODIUM AND PSEUDOEPHEDRINE HYDROCHLORIDE	naproxen sodium; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	211360	ANDA	VESPYR BRANDS, INC.	71179-816-24	3 BLISTER PACK in 1 CARTON (71179-816-24) / 8 TABLET, EXTENDED RELEASE in 1 BLISTER PACK	2024-08-07

Naproxen Sodium and Pseudoephedrine Hydrochloride Drug Supplier Landscape

Last updated: February 19, 2026

What is the current supply chain status for Naproxen Sodium and Pseudoephedrine Hydrochloride?

The global supply chain for Naproxen Sodium and Pseudoephedrine Hydrochloride is characterized by established manufacturing bases, a tiered supplier structure, and evolving regulatory oversight impacting sourcing and production. Key manufacturing hubs are located in China and India, with some smaller-scale production also present in North America and Europe. The market is mature, with significant capacity to meet existing demand for both active pharmaceutical ingredients (APIs).

Naproxen Sodium

Naproxen Sodium is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve pain, inflammation, and fever. Its production involves multi-step chemical synthesis.

Major Manufacturers and Suppliers (Indicative List):

• China:
  • Zhejiang NHU Co., Ltd.: A significant producer of APIs, including Naproxen Sodium.
  • Anhui Chem-Eagle Pharmaceutical Co., Ltd.: Engaged in the production of various pharmaceutical intermediates and APIs.
  • Hubei Biocause Pharmaceutical Co., Ltd.: Manufactures APIs for both human and veterinary use.
• India:
  • Dr. Reddy's Laboratories: A large pharmaceutical company with API manufacturing capabilities.
  • Sun Pharmaceutical Industries Ltd.: A major global pharmaceutical player with extensive API production.
  • Divi's Laboratories: Specializes in the manufacture of APIs and intermediates.
• Europe:
  • Bachem AG (Switzerland): While primarily focused on peptides, some API production capabilities exist.
• North America:
  • While significant formulation occurs, API production in North America is less dominant compared to Asia for this specific compound.

Typical Production Capacity: Large-scale manufacturers can produce metric tons of Naproxen Sodium annually. Specific capacity figures are often proprietary but are understood to be sufficient for global demand.

Quality Standards: Manufacturers typically adhere to Good Manufacturing Practices (GMP) as mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. This includes compliance with pharmacopeial standards like the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP).

Pseudoephedrine Hydrochloride

Pseudoephedrine Hydrochloride is a decongestant, commonly found in over-the-counter cold and allergy medications. Its production is more tightly regulated due to its potential for diversion into illicit methamphetamine production.

Major Manufacturers and Suppliers (Indicative List):

• China:
  • Hebei Chengxin Pharmaceutical Co., Ltd.: A key supplier of various pharmaceutical chemicals.
  • Jiangsu Kaimen Chemical Co., Ltd.: Involved in the synthesis of pharmaceutical intermediates and APIs.
  • Yantai Tayho Pharmaceutical Co., Ltd.: Manufactures a range of pharmaceutical raw materials.
• India:
  • Laurus Labs Limited: A prominent API manufacturer with a broad product portfolio.
  • Aarti Industries Limited: Manufactures specialty chemicals and pharmaceuticals, including APIs.
  • Granules India Ltd.: A large producer of APIs and pharmaceutical intermediates.
• North America:
  • Perrigo Company plc (Ireland/USA): While a major finished dosage form manufacturer, has had API sourcing and some manufacturing presence.
  • Specific API manufacturers may exist but are often niche and subject to strict controls.

Regulatory Considerations for Pseudoephedrine Hydrochloride: The sale and distribution of Pseudoephedrine Hydrochloride are subject to stringent regulations in many countries, including the Combat Methamphetamine Epidemic Act (CMEA) in the United States. This legislation imposes limits on purchase quantities, requires identification for over-the-counter sales, and mandates behind-the-counter placement. These regulations directly impact the logistics and distribution channels for this API.

Production Process: Pseudoephedrine is often derived from ephedrine, which can be synthesized or extracted. The hydrochloride salt is then formed.

Quality Standards: Similar to Naproxen Sodium, GMP compliance and adherence to USP/EP standards are mandatory.

What are the primary raw material sourcing challenges for these APIs?

Sourcing raw materials for both Naproxen Sodium and Pseudoephedrine Hydrochloride involves managing supply chain complexity, geopolitical risks, and fluctuating input costs.

Naproxen Sodium Raw Materials:

Key precursors for Naproxen Sodium synthesis include:

• 2-Methoxynaphthalene: A critical starting material.
• Propionic acid derivatives: Such as methyl propionate or propionyl chloride.
• Various reagents and solvents: Including catalysts, bases, and extraction solvents.

Sourcing Challenges:

• Geographic Concentration: A significant portion of 2-methoxynaphthalene and related intermediates are produced in China. Disruptions in China, whether due to environmental regulations, trade disputes, or public health crises, can impact global availability.
• Price Volatility: The cost of petrochemical-derived inputs can fluctuate with global energy prices.
• Supplier Qualification: Ensuring consistent quality and reliability from upstream suppliers requires rigorous auditing and qualification processes.

Pseudoephedrine Hydrochloride Raw Materials:

The synthesis of Pseudoephedrine Hydrochloride can involve:

• Ephedrine or Pseudoephedrine base: This is the direct precursor.
• Hydrochloric acid: Used for salt formation.
• Solvents and catalysts: For synthesis and purification.

Sourcing Challenges:

• Ephedrine/Pseudoephedrine Regulation: The primary challenge is the tight regulatory control over ephedrine and pseudoephedrine itself, due to its illicit use. Manufacturers often require specific licenses and demonstrate robust security measures for handling these materials.
• Limited Number of Primary Producers: The pool of legitimate primary producers of ephedrine and pseudoephedrine is smaller than for many other APIs, leading to concentrated supply.
• Geopolitical Instability: Sourcing can be affected by the political stability and regulatory environment in countries where ephedrine is produced or processed.

What are the key regulatory hurdles impacting manufacturers and suppliers?

Regulatory compliance is a critical operational aspect for manufacturers and suppliers of Naproxen Sodium and Pseudoephedrine Hydrochloride, affecting market access, production processes, and distribution.

General API Regulatory Hurdles:

• Good Manufacturing Practices (GMP): All manufacturing facilities must comply with current GMP standards as defined by regulatory authorities (FDA, EMA, WHO, etc.). This includes stringent controls on quality management systems, facility design, personnel training, documentation, and process validation.
  • FDA: cGMP regulations (21 CFR Parts 210 and 211).
  • EMA: EudraLex Volume 4.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. These confidential documents detail the manufacturing process, quality control, and specifications of the API. Customers (finished drug manufacturers) can reference these DMFs in their drug applications.
• Inspections and Audits: Facilities are subject to regular inspections by regulatory authorities and audits by customers. Non-compliance can lead to warning letters, import alerts, or product recalls.
• Environmental, Health, and Safety (EHS) Regulations: Increasingly stringent EHS regulations, particularly in China and India, impact chemical manufacturing. This includes wastewater treatment, emissions control, and waste disposal, which can increase operating costs and lead to temporary plant closures for upgrades.

Specific Regulatory Hurdles for Pseudoephedrine Hydrochloride:

• Controlled Substance Regulations: In many jurisdictions, pseudoephedrine and its precursors are classified as controlled substances or precursor chemicals. This necessitates:
  • Licensing and Registration: Manufacturers, distributors, and importers must obtain specific licenses from drug enforcement agencies (e.g., DEA in the U.S.).
  • Record Keeping and Reporting: Strict protocols for tracking the production, sale, and inventory of pseudoephedrine are required. This includes reporting suspicious transactions.
  • Security Measures: Robust physical security for storage and handling is mandated to prevent diversion.
• International Narcotics Control Board (INCB) Quotas: For international trade, adherence to INCB recommendations and national quotas for ephedrine and pseudoephedrine is necessary.
• Retail Sale Restrictions (Impact on API Demand): Regulations governing the retail sale of finished products containing pseudoephedrine (e.g., CMEA in the U.S.) directly influence the demand for the API, as manufacturers must forecast based on these retail limitations.

Naproxen Sodium Specific Considerations:

• Purity and Impurity Profiling: Regulatory bodies have strict requirements for the purity of APIs and the identification and control of impurities, including genotoxic impurities. Manufacturers must demonstrate robust analytical methods and process controls.
• Stability Studies: Comprehensive stability data is required to establish shelf-life and storage conditions.

What is the competitive landscape among API suppliers?

The competitive landscape for Naproxen Sodium and Pseudoephedrine Hydrochloride APIs is mature and segmented, characterized by both large, diversified players and smaller, specialized manufacturers.

Key Competitive Factors:

• Cost Competitiveness: Due to the commoditized nature of many APIs, cost of production remains a significant differentiator. Manufacturers in lower-cost regions like China and India often have a cost advantage.
• Quality and Compliance: A strong track record of GMP compliance and successful regulatory inspections is paramount. Suppliers with a history of FDA/EMA approvals and no warning letters are preferred.
• Reliability of Supply: Consistent production capacity, robust supply chain management, and the ability to mitigate disruptions are critical for maintaining customer loyalty.
• Technical Expertise and Process Innovation: While mature, ongoing efforts to optimize synthesis routes, improve yields, and reduce environmental impact can provide a competitive edge.
• Regulatory Support: The ability to provide comprehensive DMFs and assist customers with their regulatory filings is essential.
• Customer Service and Responsiveness: Prompt communication, technical support, and flexible order fulfillment are valued.

Market Structure:

• Dominance of Asian Manufacturers: China and India are the dominant manufacturing regions, accounting for a large percentage of global API production for both Naproxen Sodium and Pseudoephedrine Hydrochloride.
• Tiered Supplier Base:
  • Tier 1: Large, vertically integrated pharmaceutical companies or dedicated API manufacturers with significant scale, broad product portfolios, and established regulatory track records. These are often preferred by major pharmaceutical brand companies.
  • Tier 2: Mid-sized manufacturers with strong regional presence or specialized capabilities.
  • Tier 3: Smaller manufacturers, often focused on intermediates or specific niche markets, may compete on price but may carry higher perceived risk for large buyers.
• Impact of Generic Competition: The market for these APIs is largely driven by generic drug manufacturers. Therefore, price is a significant consideration, and suppliers who can offer competitive pricing while meeting quality standards are favored.
• Consolidation Trends: The pharmaceutical API sector has seen periods of consolidation, with larger companies acquiring smaller players to expand their product portfolios or geographic reach.

What are the outlook and emerging trends for these APIs?

The outlook for Naproxen Sodium and Pseudoephedrine Hydrochloride APIs is stable, with moderate growth driven by the continued demand for pain relief and cold/allergy medications. However, emerging trends will shape the supply and demand dynamics.

Outlook:

• Stable Demand: Both APIs are well-established in the pharmaceutical market. Demand is expected to remain consistent, driven by aging populations (increased pain management needs) and the prevalence of respiratory illnesses.
• Generic Market Dominance: The majority of Naproxen Sodium and Pseudoephedrine Hydrochloride is used in generic formulations, leading to a price-sensitive market.
• Limited Innovation in API Synthesis: Significant breakthroughs in the synthesis of these mature molecules are unlikely. Focus will be on incremental process improvements for efficiency and sustainability.

Emerging Trends:

• Increased Supply Chain Scrutiny and Resilience: Events like the COVID-19 pandemic have highlighted the vulnerabilities of global supply chains. Pharmaceutical companies are increasingly seeking to diversify their supplier base, reshore some manufacturing, and build greater resilience. This may lead to a modest increase in North American or European manufacturing for critical APIs, though cost remains a barrier.
• Enhanced Regulatory Harmonization and Enforcement: Regulatory bodies worldwide are continuing to harmonize standards and increase enforcement, particularly concerning data integrity and impurity control. Suppliers must invest in robust quality systems to meet these evolving expectations.
• Focus on Sustainability and Green Chemistry: Growing pressure from consumers, investors, and regulators is driving manufacturers to adopt more sustainable production methods, including reducing solvent use, minimizing waste, and improving energy efficiency. This could favor suppliers who invest in green chemistry initiatives.
• Digitalization of Supply Chains: The adoption of digital technologies for supply chain management, inventory tracking, and quality control is increasing. This can improve transparency, traceability, and efficiency.
• Geopolitical Influences: Trade policies, tariffs, and international relations can significantly impact the cost and availability of APIs, particularly those with concentrated manufacturing bases. Companies will need to monitor geopolitical developments closely.
• Regulatory Evolution for Pseudoephedrine: Ongoing efforts to combat methamphetamine production may lead to further regulatory adjustments concerning the sale and distribution of pseudoephedrine, potentially impacting market access and logistics for API suppliers and finished product manufacturers.

Strategic Considerations for Stakeholders:

• Diversification of Supply Base: For pharmaceutical companies, reducing reliance on single-source or single-region suppliers is a key strategic imperative.
• Investment in Quality Systems: Continuous investment in GMP compliance and advanced quality control is essential for market access and long-term viability.
• Proactive Regulatory Monitoring: Staying abreast of evolving regulatory requirements, particularly for pseudoephedrine, is critical.
• Supply Chain Risk Assessment: Robust risk assessment and mitigation strategies for raw material sourcing and manufacturing operations are necessary.

Key Takeaways

• The global supply of Naproxen Sodium and Pseudoephedrine Hydrochloride is dominated by manufacturers in China and India, with established capacity to meet current demand.
• Sourcing raw materials faces challenges related to geographic concentration, price volatility, and, for pseudoephedrine, stringent regulatory controls aimed at preventing diversion.
• Manufacturers must adhere to rigorous GMP standards, with Pseudoephedrine Hydrochloride subject to additional controlled substance regulations.
• The competitive landscape is mature and cost-driven, with quality, reliability, and regulatory compliance as key differentiators.
• Future trends include increased supply chain scrutiny, enhanced regulatory enforcement, a focus on sustainability, and the ongoing impact of geopolitical factors.

FAQs

1. How are geopolitical tensions impacting the supply of these APIs? Geopolitical tensions can disrupt trade flows, increase transportation costs, and lead to tariffs or import restrictions, thereby affecting the cost and availability of APIs sourced from or transiting through affected regions. For example, trade disputes between major manufacturing nations can create uncertainty for supply chain planning.

2. What is the typical lead time for ordering bulk Naproxen Sodium or Pseudoephedrine Hydrochloride from Asian suppliers? Typical lead times can range from 8 to 16 weeks from order placement to delivery. This includes manufacturing time, quality control release, and shipping logistics. However, these lead times can be extended by factors such as production backlogs, raw material shortages, or shipping delays.

3. Are there significant risks associated with single-source procurement of these APIs? Yes, single-source procurement presents significant risks, including potential supply disruptions due to the supplier's operational issues, regulatory non-compliance, quality deviations, or geopolitical events affecting their region. It also limits negotiation leverage.

4. What due diligence is essential when selecting a new API supplier for Pseudoephedrine Hydrochloride? Due diligence must include verification of the supplier's controlled substance registrations and licenses, a thorough review of their security protocols for handling and storing pseudoephedrine, their GMP compliance history (including recent audit reports and inspection outcomes), financial stability, and their ability to provide comprehensive regulatory documentation.

5. How does the cost of regulatory compliance affect the final API price? The cost of maintaining GMP compliance, conducting validation studies, investing in quality control laboratories, meeting EHS standards, and managing controlled substance tracking (for pseudoephedrine) are significant operational expenses. These costs are factored into the final API price, making compliance a substantial component of overall production economics.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (cGMP) Regulations. Retrieved from [FDA website] [2] European Medicines Agency. (n.d.). EudraLex - The Rules Governing Medicinal Products in the European Union. Retrieved from [EMA website] [3] International Narcotics Control Board. (n.d.). Precursors. Retrieved from [INCB website] [4] U.S. Drug Enforcement Administration. (n.d.). Combat Methamphetamine Epidemic Act of 2005. Retrieved from [DEA website]